Activation of the TBK1-IFN pathway by MEDI2228 enhances CD38 expression in multiple myeloma cells, thereby augmenting the anti-tumor effects of CD38-targeting antibody-drug conjugates (87). The gene discussed is IFNA1; the disease is neoplasm.